Cognitive Impairment Associated with Mild to Moderate Migraine Episodes: Possible Effects on Workplace Attendance - Top-Institutions - MDSpire

Cognitive Impairment Associated with Mild to Moderate Migraine Episodes: Possible Effects on Workplace Attendance

  • By

  • Yoji Yamaguchi

  • Masaaki Kohta

  • Kenji Ishikawa

  • Yasuo Naito

  • Michio Yamaguchi

  • Yusuke Ikeuchi

  • Hiroyasu Shose

  • Kazuhiro Tanaka

  • Atsushi Fujita

  • Takashi Sasayama

  • March 4, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Headache Medicine
    • Neuropsychology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neuroscience
    • Headache Medicine

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Pain Medicine
    • Neuropsychology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Headache Medicine
    • Cognitive Neuroscience

  • #5

    National Institute of Neurological Disorders and Stroke (NINDS), NIH
    National Institute of Neurological Disorders and Stroke (NINDS), NIH

    Bethesda, MD

    Key Differentiators

    • Neurology
    • Neuroscience Research
    • Headache Disorders

Original Source(s)

Cognitive Impairment Associated with Mild to Moderate Migraine Episodes: Possible Effects on Workplace Attendance

  • by Yoji Yamaguchi, Masaaki Kohta, Kenji Ishikawa, Yasuo Naito, Michio Yamaguchi, Yusuke Ikeuchi, Hiroyasu Shose, Kazuhiro Tanaka, Atsushi Fujita, Takashi Sasayama

  • March 4, 2026

Related Content

Migraine with comorbid fibromyalgia: psychological burden and impact on frequency and severity of migraine attacks

Migraine, comorbidity, and risks of severe maternal and neonatal morbidity or mortality: a population-based cohort study

Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan